Immuron shares rise 10.63% premarket ahead of CEO's antibody platform presentation at Emerging Growth Conference.

Immuron surged 10.63% in premarket trading following the announcement that its CEO, Steven Lydeamore, will present the company’s antibody platform at the Emerging Growth Conference on 22 October. The virtual presentation is expected to highlight strategic developments in Immuron’s pipeline, potentially attracting investor interest in its therapeutic innovations. The move aligns with the stock’s upward trajectory, suggesting market optimism about the platform’s commercial or partnership potential.